Almotriptan for Menstrually Related Migraine
Author Information
Author(s): Gianni Allais, Gennaro Bussone, Giovanni D’Andrea, Franca Moschiano, Florindo d’Onofrio, Fabio Valguarnera, Gian Camillo Manzoni, Licia Grazzi, Rita Allais, Chiara Benedetto, Giancarlo Acuto
Primary Institution: University of Turin, Italy
Hypothesis
Almotriptan is more effective than placebo for treating menstrually related migraine.
Conclusion
Almotriptan was significantly more effective than placebo in women with menstrually related migraine attacks.
Supporting Evidence
- 48.4% of patients were pain-free at two hours after taking almotriptan compared to 26.2% with placebo.
- Almotriptan showed consistent efficacy across three migraine attacks.
- Nausea and photophobia were significantly less frequent with almotriptan.
- 39.3% of patients used rescue medication with almotriptan compared to 59.8% with placebo.
- The duration of migraine attacks was shorter with almotriptan (7.5 hours) compared to placebo (10.8 hours).
- 56.2% of patients were pain-free at two hours at least twice during the study.
Takeaway
This study found that a medication called almotriptan helps women with migraines that happen around their periods feel better faster than a fake pill.
Methodology
The study was a randomized, double-blind, placebo-controlled crossover trial involving premenopausal women with menstrually related migraine.
Potential Biases
The success of blinding was not formally evaluated during the study.
Limitations
The study was not powered to detect differences in post-hoc analyses of mild and moderate/severe subgroups.
Participant Demographics
Premenopausal women aged 18–50 years, all Caucasian.
Statistical Information
P-Value
p=0.0008
Confidence Interval
95% CI, 1.28–2.57
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website